<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347255</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 90100-01</org_study_id>
    <secondary_id>2011-000153-23</secondary_id>
    <nct_id>NCT01347255</nct_id>
  </id_info>
  <brief_title>A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris</brief_title>
  <official_title>A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the anti-psoriatic effect of LEO 90100 cutaneous
      spray ointment, using the psoriasis plaque test modified from the method developed by KJ
      Dumas and JR Scholtz.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline</measure>
    <time_frame>Day 1 (Baseline)/Day 29</time_frame>
    <description>TCS range from 0 (all signs absent) to 9 (all signs severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Sign Scores</measure>
    <time_frame>Baseline and Days 4, 8, 11, 15, 18, 22, 25, and 29 (End of Treatment)</time_frame>
    <description>Absolute change in score of each clinical sign (erythema, scaling, infiltration) at end of treatment (Day 29) and at individual visits (Days 4, 8, 11, 15, 18, 22, and 25) compared to Baseline.
The investigator assessed the severity of the clinical signs erythema, scaling, and infiltration for each test site by using a 7-point scale (range 0 (no evidence) to 3 (severe)).
Negative changes in mean score represent improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Total Clinical Score (TCS) by Visit</measure>
    <time_frame>Baseline and Days 4, 8, 11, 15, 18, 22, 25</time_frame>
    <description>Change in Total Clinical Score (TCS; range from 0 (all signs absent) to 9 (all signs severe)) at individual visits (Days 4, 8, 11, 15, 22, and 25) compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Echo-poor Band Thickness at End of Treatment</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Change in echo-poor band thickness from baseline to end of treatment, measured by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Total Skin Thickness</measure>
    <time_frame>Baseline and Days 8, 15, 22, and 29.</time_frame>
    <description>Change in total skin thickness measured by ultrasound at end of treatment (Day 29) and individual visits (Days 8, 15, and 22) compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 90100 cutaneous spray ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 90100 Cutaneous Spray, Ointment, Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daivobet® Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO90100 cutaneous spray, ointment</intervention_name>
    <description>once daily application, 4 weeks</description>
    <arm_group_label>LEO 90100 cutaneous spray ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate</intervention_name>
    <description>once daily application, 4 weeks</description>
    <arm_group_label>LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100 cutaneous spray, ointment, vehicle</intervention_name>
    <description>once daily application, 4 weeks</description>
    <arm_group_label>LEO 90100 Cutaneous Spray, Ointment, Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivobet® ointment</intervention_name>
    <description>once daily application, 4 weeks</description>
    <arm_group_label>Daivobet® Ointment</arm_group_label>
    <other_name>Taclonex® ointment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects having signed and dated an informed consent

          2. Age 18 years or above

          3. Either sex

          4. All skin types

          5. Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs
             and/or trunk.

        Exclusion Criteria:

          1. Females who are pregnant, of child-bearing potential and who wish to become pregnant
             during the study, or who are breast feeding

          2. Systemic treatment with biological therapies (marketed or not marketed) with a
             possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months
             (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 half-lives
             (which-ever is longer)for experimental biological products prior to randomisation and
             during the study

          3. Systemic treatments with all other therapies than biologicals, with a potential effect
             on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within
             the 4- week period prior to randomisation and during the study

          4. Use of phototherapy within the following time periods prior to randomisation and
             during the study:

               -  PUVA or Grenz ray therapy (4 weeks)

               -  UVB (2 weeks)

          5. Subjects using one of the following topical drugs within 4 weeks prior to
             randomisation and during the study:

               -  Potent or very potent (WHO group III-IV) corticosteroids

          6. Subjects using one of the following topical drugs for the treatment of psoriasis
             within 2 weeks prior to randomisation and during the study:

               -  WHO group I-II corticosteroids (except if used for treatment of scalp and/or
                  facial psoriasis)

               -  Topical retinoids

               -  Vitamin D analogues

               -  Topical immunomodulators (e.g. calcineurin inhibitors)

               -  Anthracen derivatives

               -  Tar

               -  Salicylic acid

          7. Subjects using emollients on the target plaques within one week before randomisation
             and during the study

          8. Initiation of, or expected changes in concomitant medication that may affect psoriasis
             vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) within
             2 weeks prior to randomisation and during the study

          9. Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular
             psoriasis

         10. Subjects with known/suspected disorders of calcium metabolism associated with
             hypercalcemia within the last 10 years, based on medical history

         11. Subjects with any of the following conditions present on the test area: viral (e.g.
             herpes or varicella) lesions of the skin, fungal and bacterial skin infections,
             parasitic infections and atrophic skin

         12. Subjects with skin manifestations in relation to syphilis or tuberculosis, rosacea,
             perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of
             skin veins, ichthyosis, acne rosacea, ulcers and wounds within the plaque test areas

         13. History of any severe disease or serious current condition (based on subject interview
             and/or results of screening physical examination) which, in the opinion of the
             Investigator, would put the subject at risk by participating in the study or would
             interfere significantly with the evaluation of study results or the study course (e.g.
             cancer, severe cardiopathy, severe renal insufficiency, severe hepatic insufficiency)

         14. Subjects who have received treatment with any non-marketed drug substance (i.e., an
             agent which has not yet been made available for clinical use following registration)
             within the 4 week period prior to randomisation or longer, if the class of the
             substance requires a longer washout as defined above (e.g., biological treatments)

         15. Subjects with current participation in any other interventional clinical trial, based
             on interview of the subject

         16. Subjects with known or suspected hypersensitivity to component(s) of the
             investigational products

         17. Subjects with any concomitant medical or dermatological disorder(s) which might
             preclude accurate evaluation of the psoriasis

         18. Subjects foreseeing an intensive solar exposure during the study (UV radiation, etc.)
             or having been exposed within two weeks preceding the screening visit

         19. Subjects impossible to contact in case of emergency

         20. Subjects who are known or, in the opinion of the investigator, are unlikely to comply
             with the Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state)

         21. Subjects who are in an exclusion period in the National Biomedical Research Register
             of the French Ministry of Health at randomisation

         22. Subjects under guardianship, hospitalized in a public or private institution, for a
             reason other than the research or subject deprived of freedom

         23. Subjects previously randomised in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Queille-Roussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Hôpital l'Archet 2, 06202 Nice Cedex 3, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD)</name>
      <address>
        <city>Nice</city>
        <zip>Cedex 3</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Queille-Roussel C, Olesen M, Villumsen J, Lacour JP. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig. 2015 Apr;35(4):239-45. doi: 10.1007/s40261-015-0269-7.</citation>
    <PMID>25708531</PMID>
  </results_reference>
  <results_reference>
    <citation>Queille-Roussel C, Olesen M, Villumsen J, Lacour JP. Antipsoriatic effect of a novel aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate in patients with psoriasis, using a modified psoriasis plaque test. Semin Cutan Med Surg. 2015;34 S1:PA-10.</citation>
  </results_reference>
  <results_reference>
    <citation>Hollesen Basse L, Olesen M, Lacour J, Queille-Roussel C. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol. 2014;134:S33(abst 192).</citation>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>November 13, 2015</results_first_submitted>
  <results_first_submitted_qc>January 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2016</results_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</doc_url>
      <doc_comment>Clinical Trials at LEO Pharma</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject First Visit: 12-MAY-2011 Last Subject Last Visit: 20-JUN-2011</recruitment_details>
      <pre_assignment_details>The study was conducted with 3 successive individual phases:
Screening Phase (washout if applic.). A medical examination was performed at screening which took place 1-21 days before the start of the treatment phase (Day 1).
Treatment Phase (All patients (N=24) received all investigational medicinal products)
Follow-up Phase (if applic.)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>All subjects received all four treatments:
LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
LEO 90100 cutaneous spray, ointment, vehicle w. betamethasone. Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)
LEO 90100 cutaneous spray, ointment, vehicle. Served as a negative control for the two cutaneous spray ointments with active ingredients
Daivobet® ointment. Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
Four test sites of approximately 5 cm2 were selected on predetermined psoriasis lesions (target plaques), delimited with a disposable circular device and mapped on a drawn figure.
The distance between two test sites was at least 2 cm. The products were applied on the four test sites (according to random assignment to specific test sites selected on the psoriasis plaque) once daily 6 days a week (except Sundays) for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intra-individual baseline analysis population</population>
      <group_list>
        <group group_id="B1">
          <title>LEO 90100 Cutaneous Spray, Ointment</title>
          <description>Intra-Individual baseline analysis population, all treated with the following four products:
LEO 90100 cutaneous spray, ointment: once daily application, 4 weeks (6 days a week)
LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate: once daily application, 4 weeks (6 days a week)
LEO 90100 cutaneous spray, ointment, vehicle: once daily application, 4 weeks (6 days a week)
Daivobet® ointment: once daily application, 4 weeks (6 days a week)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline</title>
        <description>TCS range from 0 (all signs absent) to 9 (all signs severe).</description>
        <time_frame>Day 1 (Baseline)/Day 29</time_frame>
        <population>Intra-individual analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Cutaneous Spray, Ointment</title>
            <description>LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).</description>
          </group>
          <group group_id="O2">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone</title>
            <description>Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
          <group group_id="O3">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle</title>
            <description>LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.</description>
          </group>
          <group group_id="O4">
            <title>Daivobet® Ointment</title>
            <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline</title>
          <description>TCS range from 0 (all signs absent) to 9 (all signs severe).</description>
          <population>Intra-individual analysis population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.00" spread="1.27"/>
                    <measurement group_id="O2" value="-4.96" spread="1.85"/>
                    <measurement group_id="O3" value="-1.88" spread="1.12"/>
                    <measurement group_id="O4" value="-5.25" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Sign Scores</title>
        <description>Absolute change in score of each clinical sign (erythema, scaling, infiltration) at end of treatment (Day 29) and at individual visits (Days 4, 8, 11, 15, 18, 22, and 25) compared to Baseline.
The investigator assessed the severity of the clinical signs erythema, scaling, and infiltration for each test site by using a 7-point scale (range 0 (no evidence) to 3 (severe)).
Negative changes in mean score represent improvement.</description>
        <time_frame>Baseline and Days 4, 8, 11, 15, 18, 22, 25, and 29 (End of Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Cutaneous Spray, Ointment</title>
            <description>LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).</description>
          </group>
          <group group_id="O2">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone</title>
            <description>Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
          <group group_id="O3">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle</title>
            <description>LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.</description>
          </group>
          <group group_id="O4">
            <title>Daivobet® Ointment</title>
            <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Sign Scores</title>
          <description>Absolute change in score of each clinical sign (erythema, scaling, infiltration) at end of treatment (Day 29) and at individual visits (Days 4, 8, 11, 15, 18, 22, and 25) compared to Baseline.
The investigator assessed the severity of the clinical signs erythema, scaling, and infiltration for each test site by using a 7-point scale (range 0 (no evidence) to 3 (severe)).
Negative changes in mean score represent improvement.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="0.71"/>
                    <measurement group_id="O2" value="-1.44" spread="0.78"/>
                    <measurement group_id="O3" value="-0.56" spread="0.47"/>
                    <measurement group_id="O4" value="-1.50" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.13" spread="0.47"/>
                    <measurement group_id="O2" value="-2.02" spread="0.58"/>
                    <measurement group_id="O3" value="-0.90" spread="0.47"/>
                    <measurement group_id="O4" value="-2.02" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.13" spread="0.45"/>
                    <measurement group_id="O2" value="-1.50" spread="0.77"/>
                    <measurement group_id="O3" value="-0.42" spread="0.43"/>
                    <measurement group_id="O4" value="-1.73" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (Day 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.32"/>
                    <measurement group_id="O2" value="-0.33" spread="0.32"/>
                    <measurement group_id="O3" value="-0.19" spread="0.25"/>
                    <measurement group_id="O4" value="-0.33" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (Day 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.35"/>
                    <measurement group_id="O2" value="-0.31" spread="0.36"/>
                    <measurement group_id="O3" value="-0.19" spread="0.25"/>
                    <measurement group_id="O4" value="-0.23" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration (Day 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.30"/>
                    <measurement group_id="O2" value="-0.13" spread="0.27"/>
                    <measurement group_id="O3" value="-0.08" spread="0.19"/>
                    <measurement group_id="O4" value="-0.17" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.42"/>
                    <measurement group_id="O2" value="-0.60" spread="0.42"/>
                    <measurement group_id="O3" value="-0.13" spread="0.37"/>
                    <measurement group_id="O4" value="-0.67" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.66"/>
                    <measurement group_id="O2" value="-0.81" spread="0.59"/>
                    <measurement group_id="O3" value="-0.21" spread="0.44"/>
                    <measurement group_id="O4" value="-0.73" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.39"/>
                    <measurement group_id="O2" value="-0.42" spread="0.43"/>
                    <measurement group_id="O3" value="-0.08" spread="0.41"/>
                    <measurement group_id="O4" value="-0.56" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (Day 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="0.46"/>
                    <measurement group_id="O2" value="-0.75" spread="0.42"/>
                    <measurement group_id="O3" value="-0.29" spread="0.39"/>
                    <measurement group_id="O4" value="-0.83" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (Day 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="0.67"/>
                    <measurement group_id="O2" value="-1.06" spread="0.70"/>
                    <measurement group_id="O3" value="-0.46" spread="0.49"/>
                    <measurement group_id="O4" value="-1.23" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration (Day 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.47"/>
                    <measurement group_id="O2" value="-0.58" spread="0.52"/>
                    <measurement group_id="O3" value="-0.23" spread="0.44"/>
                    <measurement group_id="O4" value="-0.90" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="0.41"/>
                    <measurement group_id="O2" value="-1.06" spread="0.52"/>
                    <measurement group_id="O3" value="-0.33" spread="0.43"/>
                    <measurement group_id="O4" value="-1.04" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="0.63"/>
                    <measurement group_id="O2" value="-1.40" spread="0.59"/>
                    <measurement group_id="O3" value="-0.46" spread="0.41"/>
                    <measurement group_id="O4" value="-1.40" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="0.44"/>
                    <measurement group_id="O2" value="-0.85" spread="0.52"/>
                    <measurement group_id="O3" value="-0.23" spread="0.44"/>
                    <measurement group_id="O4" value="-1.06" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="0.43"/>
                    <measurement group_id="O2" value="-1.20" spread="0.62"/>
                    <measurement group_id="O3" value="-0.35" spread="0.41"/>
                    <measurement group_id="O4" value="-1.35" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="0.57"/>
                    <measurement group_id="O2" value="-1.52" spread="0.67"/>
                    <measurement group_id="O3" value="-0.67" spread="0.44"/>
                    <measurement group_id="O4" value="-1.74" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration (Day 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="0.54"/>
                    <measurement group_id="O2" value="-1.11" spread="0.62"/>
                    <measurement group_id="O3" value="-0.30" spread="0.45"/>
                    <measurement group_id="O4" value="-1.43" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="0.55"/>
                    <measurement group_id="O2" value="-1.29" spread="0.46"/>
                    <measurement group_id="O3" value="-0.52" spread="0.43"/>
                    <measurement group_id="O4" value="-1.44" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="0.54"/>
                    <measurement group_id="O2" value="-1.73" spread="0.64"/>
                    <measurement group_id="O3" value="-0.67" spread="0.48"/>
                    <measurement group_id="O4" value="-1.81" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="0.50"/>
                    <measurement group_id="O2" value="-1.35" spread="0.67"/>
                    <measurement group_id="O3" value="-0.38" spread="0.42"/>
                    <measurement group_id="O4" value="-1.50" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="0.53"/>
                    <measurement group_id="O2" value="-1.44" spread="0.68"/>
                    <measurement group_id="O3" value="-0.56" spread="0.43"/>
                    <measurement group_id="O4" value="-1.56" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="0.50"/>
                    <measurement group_id="O2" value="-1.98" spread="0.60"/>
                    <measurement group_id="O3" value="-0.85" spread="0.38"/>
                    <measurement group_id="O4" value="-1.98" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltration (Day 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.10" spread="0.49"/>
                    <measurement group_id="O2" value="-1.52" spread="0.67"/>
                    <measurement group_id="O3" value="-0.44" spread="0.37"/>
                    <measurement group_id="O4" value="-1.67" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Total Clinical Score (TCS) by Visit</title>
        <description>Change in Total Clinical Score (TCS; range from 0 (all signs absent) to 9 (all signs severe)) at individual visits (Days 4, 8, 11, 15, 22, and 25) compared to baseline.</description>
        <time_frame>Baseline and Days 4, 8, 11, 15, 18, 22, 25</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Cutaneous Spray, Ointment</title>
            <description>LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).</description>
          </group>
          <group group_id="O2">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone</title>
            <description>Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
          <group group_id="O3">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle</title>
            <description>LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.</description>
          </group>
          <group group_id="O4">
            <title>Daivobet® Ointment</title>
            <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Total Clinical Score (TCS) by Visit</title>
          <description>Change in Total Clinical Score (TCS; range from 0 (all signs absent) to 9 (all signs severe)) at individual visits (Days 4, 8, 11, 15, 22, and 25) compared to baseline.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.65"/>
                    <measurement group_id="O2" value="-0.77" spread="0.71"/>
                    <measurement group_id="O3" value="-0.46" spread="0.36"/>
                    <measurement group_id="O4" value="-0.73" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="1.17"/>
                    <measurement group_id="O2" value="-1.83" spread="1.03"/>
                    <measurement group_id="O3" value="-0.42" spread="0.83"/>
                    <measurement group_id="O4" value="-1.96" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.38" spread="1.17"/>
                    <measurement group_id="O2" value="-2.40" spread="1.38"/>
                    <measurement group_id="O3" value="-0.98" spread="0.87"/>
                    <measurement group_id="O4" value="-2.96" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.25" spread="1.07"/>
                    <measurement group_id="O2" value="-3.31" spread="1.31"/>
                    <measurement group_id="O3" value="-1.02" spread="0.94"/>
                    <measurement group_id="O4" value="-3.50" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.85" spread="1.17"/>
                    <measurement group_id="O2" value="-3.83" spread="1.66"/>
                    <measurement group_id="O3" value="-1.33" spread="1.00"/>
                    <measurement group_id="O4" value="-4.52" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.71" spread="1.17"/>
                    <measurement group_id="O2" value="-4.38" spread="1.49"/>
                    <measurement group_id="O3" value="-1.56" spread="1.08"/>
                    <measurement group_id="O4" value="-4.75" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.04" spread="1.15"/>
                    <measurement group_id="O2" value="-4.94" spread="1.68"/>
                    <measurement group_id="O3" value="-1.85" spread="0.88"/>
                    <measurement group_id="O4" value="-5.21" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Echo-poor Band Thickness at End of Treatment</title>
        <description>Change in echo-poor band thickness from baseline to end of treatment, measured by ultrasound</description>
        <time_frame>Baseline and Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Cutaneous Spray, Ointment</title>
            <description>LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).</description>
          </group>
          <group group_id="O2">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone</title>
            <description>Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
          <group group_id="O3">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle</title>
            <description>LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.</description>
          </group>
          <group group_id="O4">
            <title>Daivobet® Ointment</title>
            <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Echo-poor Band Thickness at End of Treatment</title>
          <description>Change in echo-poor band thickness from baseline to end of treatment, measured by ultrasound</description>
          <units>millimetres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.21"/>
                    <measurement group_id="O2" value="-0.45" spread="0.25"/>
                    <measurement group_id="O3" value="-0.12" spread="0.20"/>
                    <measurement group_id="O4" value="-0.46" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Total Skin Thickness</title>
        <description>Change in total skin thickness measured by ultrasound at end of treatment (Day 29) and individual visits (Days 8, 15, and 22) compared to baseline</description>
        <time_frame>Baseline and Days 8, 15, 22, and 29.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Cutaneous Spray, Ointment</title>
            <description>LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).</description>
          </group>
          <group group_id="O2">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone</title>
            <description>Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
          <group group_id="O3">
            <title>LEO 90100 Cutaneous Spray, Ointment, Vehicle</title>
            <description>LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.</description>
          </group>
          <group group_id="O4">
            <title>Daivobet® Ointment</title>
            <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Total Skin Thickness</title>
          <description>Change in total skin thickness measured by ultrasound at end of treatment (Day 29) and individual visits (Days 8, 15, and 22) compared to baseline</description>
          <units>millimetres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.41"/>
                    <measurement group_id="O2" value="-0.66" spread="0.42"/>
                    <measurement group_id="O3" value="-0.23" spread="0.30"/>
                    <measurement group_id="O4" value="-0.62" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.31"/>
                    <measurement group_id="O2" value="-0.28" spread="0.19"/>
                    <measurement group_id="O3" value="-0.07" spread="0.21"/>
                    <measurement group_id="O4" value="-0.33" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.38"/>
                    <measurement group_id="O2" value="-0.40" spread="0.29"/>
                    <measurement group_id="O3" value="-0.12" spread="0.23"/>
                    <measurement group_id="O4" value="-0.49" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.40"/>
                    <measurement group_id="O2" value="-0.59" spread="0.35"/>
                    <measurement group_id="O3" value="-0.18" spread="0.25"/>
                    <measurement group_id="O4" value="-0.59" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LEO 90100 Cutaneous Spray, Ointment</title>
          <description>Intra-Individual baseline analysis population, all treated with the following four products:
LEO 90100 cutaneous spray, ointment: once daily application, 4weeks
LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate: once daily application, 4 weeks
LEO 90100 cutaneous spray, ointment, vehicle: once daily application, 4weeks
Daivobet® ointment: once daily application, 4weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 44945888</phone>
      <email>ctr.disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

